{"id":17002,"date":"2022-04-14T19:45:34","date_gmt":"2022-04-14T14:15:34","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=17002"},"modified":"2023-04-04T11:24:57","modified_gmt":"2023-04-04T05:54:57","slug":"medtech-news-for-alcon-ivasc-paige-truvic-alucent","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-alcon-ivasc-paige-truvic-alucent","title":{"rendered":"Alcon\u2019s Dry Eye Treatment Device; I-VASC Secures Series A Funding; Paige\u2019s AI Medical Device Software; TRUVIC\u2019s Prodigy Thrombectomy System; Alucent\u2019s Natural Vascular Scaffolding Technology; Guardant Presents Data Supporting Efficacy of Blood Test in Detecting Multiple Cancers"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-6a032d734c4f7\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-6a032d734c4f7\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-alcon-ivasc-paige-truvic-alucent\/#Alcon_Announces_Launch_of_Dry_Eye_Treatment_Device\" >Alcon Announces Launch of Dry Eye Treatment Device<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-alcon-ivasc-paige-truvic-alucent\/#AI_Medical_Device_Software_by_Paige_Receives_CE-IVD_and_UKCA_Marks\" >AI Medical Device Software by Paige Receives CE-IVD and UKCA Marks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-alcon-ivasc-paige-truvic-alucent\/#I-VASC_Srl_Obtains_Series_A_Funding_to_Launch_its_Chronic_Venous_Insufficiency_Device\" >I-VASC Srl Obtains Series A Funding to Launch its Chronic Venous Insufficiency Device<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-alcon-ivasc-paige-truvic-alucent\/#TRUVIC_Receives_510_k_Clearance_for_the_Prodigy%E2%84%A2_Thrombectomy_System\" >TRUVIC Receives 510 (k) Clearance for the Prodigy&#x2122; Thrombectomy System<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-alcon-ivasc-paige-truvic-alucent\/#Guardant_Health_Presents_New_Data_Supporting_Efficacy_of_Blood_Test_in_Detecting_Multiple_Cancers\" >Guardant Health Presents New Data Supporting Efficacy of Blood Test in Detecting Multiple Cancers<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-alcon-ivasc-paige-truvic-alucent\/#Alucent_Biomedical_Announces_Enrollment_of_First_Patient_in_First_in_Human_Natural_Vascular_Scaffolding_Clinical_Trial\" >Alucent Biomedical Announces Enrollment of First Patient in First in Human Natural Vascular Scaffolding Clinical Trial<\/a><\/li><\/ul><\/nav><\/div>\n\n<h2 class=\"wp-block-heading\" id=\"h-alcon-announces-launch-of-dry-eye-treatment-device\"><span class=\"ez-toc-section\" id=\"Alcon_Announces_Launch_of_Dry_Eye_Treatment_Device\"><\/span><strong>Alcon Announces Launch of Dry Eye Treatment Device<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On<strong> April 04, 2022, Alcon Inc.<\/strong> announced the launch of their latest dry eye innovation, the <strong>Systane\u00ae iLux2\u00ae Meibomian Gland Dysfunction (MGD) Thermal Pulsation System<\/strong>. It is an all-in-one handheld device equipped with new imaging technology to capture infrared photos and HD video of the meibomian glands which will allow patients to see the need for treatment and visualize their procedure, and experience\u202fresults in as little as one week.<\/p>\n\n\n\n<p>The Systane iLux2 MGD Thermal Pulsation System would further expand Alcon\u2019s current dry eye treatment offerings and allow practitioners to tailor MGD treatment to the needs of each of their patients in eight to twelve minutes.<\/p>\n\n\n\n<p>The device is equipped with imaging technology that allows patients to view both their meibomian glands and treatment through infrared imaging and HD video of the procedure.<\/p>\n\n\n\n<p>ECPs can customize heat and compression across each easy-to-visualize treatment zone.<\/p>\n\n\n\n<p>Systane iLux2 MGD Thermal Pulsation System can help Eye Care Practitioners build a strong, trusting relationship with their patients by boosting the credibility of their treatment recommendation through direct visualization of the disease and tracking the disease over time through stored meibomian gland images.<\/p>\n\n\n\n<p>Fred Ellis, Vice President, U.S. Pharmaceutical and Dry Eye, Alcon mentioned, <em>\u201cAlcon is dedicated to the advancement of medical device technology and providing Eye Care Professionals (ECPs) with the tools needed to effectively treat their patients.\u201d He further added<\/em> <em>\u201cWith the Systane iLux2 MGD Thermal Pulsation System, ECPs will be able to further patient trust and confidence because seeing is believing.\u201d&nbsp;<\/em><\/p>\n\n\n\n<p>Eric D. Donnenfeld, M.D., FAAO, Ophthalmic Consultants of Long Island, NY, said, <em>\u201cThe new Systane iLux2 MGD Thermal Pulsation System gives me the confidence to customize treatments based on my patients\u2019 needs and help them see, understand and value their MGD treatment.\u201d<\/em><\/p>\n\n\n\n<p>As per <strong>DelveInsight analysis<\/strong>, the entry of such devices would help in better management of ophthalmic indications which would positively influence the growth of the ophthalmic devices market. According to DelveInsight\u2019s \u201c<a href=\"https:\/\/www.delveinsight.com\/report-store\/ophthalmic-devices-market\"><strong>Ophthalmic Devices Market<\/strong><\/a><strong>\u201d <\/strong>report, the global ophthalmic devices market was valued at <strong>USD 55.91 billion<\/strong> in 2021, growing at a CAGR of <strong>4.12%<\/strong> during the forecast period from 2022 to 2027 to reach <strong>USD 71.23 billion<\/strong> by 2027. The demand for ophthalmic devices is primarily being boosted by the rising prevalence of myopia and growing geriatric population base which has resulted in the increased prevalence of ocular diseases of different etiologies, increasing number of ophthalmic surgeries, and technical innovation in product development which are expected to increase the product demand thereby contributing in the growth of the ophthalmic devices market during the forecast period from 2022-2027.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"AI_Medical_Device_Software_by_Paige_Receives_CE-IVD_and_UKCA_Marks\"><\/span><strong>AI Medical Device Software by Paige Receives CE-IVD and UKCA Marks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On<strong> April 06, 2022, <\/strong>Paige received the CE-IVD and UKCA marks for Paige Breast Lymph Node which is a clinical AI application.&nbsp;<\/p>\n\n\n\n<p>The newly launched AI medical device software is aimed to help pathologists detect if breast cancer has metastasized to lymph nodes, concurrent with pathologists\u2019 own interpretive review. These CE-IVD and UKCA designations would enable the hospitals and laboratories in the European Economic Area, the UK, and Switzerland to use the product in the course of clinical diagnosis.&nbsp;<\/p>\n\n\n\n<p>Paige Breast Lymph Node is based on the same underlying <a href=\"https:\/\/www.delveinsight.com\/blog\/top-applications-of-artificial-intelligence-in-healthcare\">AI technology<\/a> as Paige Prostate and can be deployed in any laboratory or hospital setting that is on the Paige Platform.<\/p>\n\n\n\n<p>Juan Retamero, M.D., Medical Director, Digital Pathology Transformation at Paige, mentioned, <em>\u201cPaige\u2019s aim is to provide pathologists with innovative, care enhancing technology so they can provide the best possible insights to patients. Through Paige Breast Lymph Node, pathologists can more efficiently identify tumor metastases of any size, including small micrometastases,\u201d <\/em>He further added, \u201cThe CE-IVD and UKCA marks for Paige Breast Lymph Node are a vital step towards increasing the adoption of our new tool in European hospitals and laboratories.\u201d<\/p>\n\n\n\n<p>However, in the United States, the Paige Breast Lymph Node is available for \u201cResearch Use Only\u201d.<\/p>\n\n\n\n<p>According to <strong>DelveInsight analysis<\/strong>, the approval of such software as medical device would prove to be beneficial in cancer diagnosis and would help the <a href=\"https:\/\/www.delveinsight.com\/report-store\/cancer-diagnostic-market\">cancer diagnostics market<\/a> grow further in coming years.&nbsp; As per the DelveInsight report, the global cancer diagnostics market was valued at <strong>USD 114.35 billion<\/strong> in 2020, growing at a CAGR of <strong>9.43%<\/strong> during the forecast period from 2021 to 2026, to reach <strong>USD 185.08 billion<\/strong> by 2026. The increase in demand for cancer diagnostic products and services is predominantly attributed to the spike in the cancer cases reported worldwide. In addition, growing manufacturers focus to develop advanced cancer diagnostic products, the establishment of various cancer diagnostic labs, and rising government initiatives to raise awareness regarding early detection and management of cancer among the patients, and others are anticipated to drive the global cancer diagnostic market during the forthcoming years.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"I-VASC_Srl_Obtains_Series_A_Funding_to_Launch_its_Chronic_Venous_Insufficiency_Device\"><\/span><strong>I-VASC Srl Obtains Series A Funding to Launch its Chronic Venous Insufficiency Device<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On<strong> April 08, 2022, &#8211; I-VASC,&nbsp; <\/strong>an<strong> <\/strong>Italy-based medical device company came up with new technology- Empty Vein Ablation (EVA) for the <a href=\"https:\/\/www.delveinsight.com\/report-store\/chronic-venous-insufficiency-market\">treatment of chronic venous insufficiency<\/a> (CVI) and varicose veins and developed a device- VELEX based on the aforementioned technology.&nbsp;<\/p>\n\n\n\n<p>The company announced the successful completion of the Series A financing round. In addition to the <strong>750K<\/strong> Euro tranche raised in the first half of 2021, the company had raised another <strong>1.066M<\/strong> Euro tranche before the end of last year, for a total amount of <strong>1.8M<\/strong> Euro in 2021. The proceeds from this round will be used by I-VASC to pay for post-market clinical studies of the VELEX &#x2122; device (which has received CE Mark approval for the European market in May 2021), to move toward FDA regulatory approval for the US market.<\/p>\n\n\n\n<p>VELEX&#x2122;, is the first CE Mark approved device of the company offers the innovative solution of the Empty Vein Ablation (EVA) technology for treating CVI, which notably includes the varicose veins disease. The device consists of a percutaneous 3-balloon catheter that allows to perform a chemical ablation (schelotherapy) in to the portion of the vein to be treated after having isolated it and emptied it from blood.<\/p>\n\n\n\n<p>Daniele Zanotti, newly appointed CEO of I-VASC, stated<em>, \u201c\u201cI am thrilled to embrace this new professional adventure and put my experience at the service of a project which has the potential of representing a new paradigm in the largely underserved market of CVI and varicose vein. With the considerable efficacy, safety and usability improvements that VELEX can offer with respect to all alternative methods, we have the opportunity to offer a better option to millions of patients and create a huge new value in the vascular arena.\u201d&nbsp;<\/em><\/p>\n\n\n\n<p>Mario Salerno, Founder and CMO of I-VASC, mentioned, <em>\u201cWe are approaching a new and important phase of the project, which I started in 2015. Thanks to the investors, who have believed in our proprietary and innovative technology, and to our reinforced team, we are now on the verge to bring VELEX&#x2122; into the market and provide proof of the validity of our EVA (Empty Vein Ablation) procedure\u201d.<\/em><\/p>\n\n\n\n<p>According to <strong>DelveInsight\u2019s analysis,<\/strong> owing to the increasing <a href=\"https:\/\/www.delveinsight.com\/report-store\/chronic-venous-insufficiency-epidemiology-forecast\">prevalence of chronic venous insufficiency<\/a> and varicose veins, rising prevalence of lifestyle disorders due to worsening of lifestyle habits, as well as continuous research and development activities to develop better treatment strategies for these indications are expected to drive the demand for such devices in coming years and would provide a conducive environment for the market growth of vein ablation devices.&nbsp;<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"TRUVIC_Receives_510_k_Clearance_for_the_Prodigy%E2%84%A2_Thrombectomy_System\"><\/span><strong>TRUVIC Receives 510 (k) Clearance for the Prodigy&#x2122; Thrombectomy System<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On<strong> April 11, 2022,<\/strong><strong> <\/strong><strong>Truvic Medical Inc, <\/strong>received 510(k) clearance from the FDA for the Prodigy&#x2122; Thrombectomy System, designed for the treatment of peripheral vascular thrombus.&nbsp;<\/p>\n\n\n\n<p>Mike Buck, CEO of Truvic, stated, <em>\u201cWe are excited to receive FDA clearance for our first thrombectomy system. We look forward to working with experts in the field to translate Prodigy\u2019s novel design elements and features into superb clinical outcomes.\u201d He further added,<\/em> <em>\u201cThis represents our first regulatory milestone as part of our strategy to advance multiple programs designed to meet patients\u2019 needs and bring more innovative technologies to the market, faster.\u201d&nbsp;<\/em><\/p>\n\n\n\n<p>Fred Khosravi, Chairman and CEO of Imperative Care, said, <em>\u201cImperative Care and Truvic share a culture of innovation and intense commitment to the needs of patients. I am pleased that these common values continue to help propel our development programs towards elevation of patient care.\u201d<\/em><\/p>\n\n\n\n<p>Truvic Medical Inc is the wholly-owned subsidiary of Imperative Care Inc.<\/p>\n\n\n\n<p>According to <strong>DelveInsight\u2019s analysis<\/strong>, the entry of new devices such as Prodigy thrombectomy system would offer physicians more options to choose from currently available devices and may help in conducting procedures with improved precision helping in better management of peripheral vascular diseases. The <a href=\"https:\/\/www.delveinsight.com\/report-store\/peripheral-vascular-devices-market\">global peripheral vascular devices market<\/a> was valued at <strong>USD 9.63 billion<\/strong> in 2021, growing at a <strong>CAGR of<\/strong> <strong>7.88%<\/strong> during the forecast period from 2022 to 2027, to reach <strong>USD 15.13 billion<\/strong> by 2027. The demand for peripheral vascular devices is primarily being boosted by the rapid growth in the prevalence of cardiovascular diseases and peripheral vascular diseases, the approval of new and advanced products, and the rising incidence of lifestyle disorders such as diabetes and hypertension. Furthermore, the increase in the geriatric population is also likely to contribute to the peripheral vascular devices market growth.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Guardant_Health_Presents_New_Data_Supporting_Efficacy_of_Blood_Test_in_Detecting_Multiple_Cancers\"><\/span><strong>Guardant Health Presents New Data Supporting Efficacy of Blood Test in Detecting Multiple Cancers<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On<strong> April 11, 2022, Guardant Health <\/strong>presented<strong> <\/strong>new data demonstrating the ability of the company\u2019s investigational next-generation Guardant SHIELD&#x2122; multi-cancer assay to accurately detect early-stage cancers. This assay is designed to analyze approximately <strong>20,000<\/strong> epigenomic biomarkers that are informative for detection of a wide range of solid tumors in a single blood test. The data for four cancer types were demonstrated as examples: colorectal, lung, pancreatic and bladder.&nbsp;<\/p>\n\n\n\n<p>Data from the presentation showed that the next-generation Guardant SHIELD multi-cancer screening assay achieved sensitivity (detection rates) of <strong>90%<\/strong> (n=692) in stages I and II colorectal cancer (CRC) and <strong>87%<\/strong> (n=55) in stages I and II lung cancer. For more advanced cancer (stages III and IV), sensitivity was <strong>93%<\/strong> (n=582) for CRC and <strong>93%<\/strong> (n=136) for lung cancer. Detection was assessed at <strong>90%<\/strong> specificity (true negative rates) based on a cohort of patients without cancer. This performance is on par with current guideline-recommended screening methods. Current screening options for these cancers, while effective, are limited due to low compliance rates: <strong>66%<\/strong> for CRC and <strong>14%<\/strong> for lung cancer. A high-performance blood test that can be completed as part of a routine patient workup has the potential to improve screening rates and, ultimately, save more lives.<\/p>\n\n\n\n<p>The investigational next-generation Guardant SHIELD multi-cancer test aims to detect early-stage cancer where there is a clinical benefit from early detection and treatment. In January 2022, Guardant Health initiated the SHIELD Lung study, a prospective, observational, multi-center basket study designed to enroll individuals undergoing cancer screening across multiple cancer types. The first cohort, or basket, will enroll nearly <strong>10,000<\/strong> individuals eligible for lung cancer screening and aims to evaluate the performance of the next-generation Guardant SHIELD test to detect lung cancer in high-risk individuals ages 50-80. The study is anticipated to run in approximately 100 centers in the United States and Europe.&nbsp;<\/p>\n\n\n\n<p>AmirAli Talasaz, Guardant Health co-CEO, said, <em>\u201cThese positive results show that the next-generation Guardant SHIELD multi-cancer assay provides sensitive detection of early-stage cancers with the ability to identify the tumor tissue of origin with high accuracy.\u201d <\/em>He further added,<em> \u201cPresentation of these positive results represents a major step forward in our commitment to offering clinicians and patients a highly sensitive blood-based multi-cancer screening test in select tumor types where we believe cancer screening can save lives.\u201d<\/em><\/p>\n\n\n\n<p>The extensive research and development activities in the liquid biopsy domain for the development of multi cancer detection assay, companion diagnostic tests among others are expected to transform the field for cancer diagnosis and treatment. According to DelveInsight\u2019s \u201c<a href=\"https:\/\/www.delveinsight.com\/report-store\/liquid-biopsy-in-cancer-diagnostics-market\"><strong>Liquid Biopsy in Cancer Diagnostics Market<\/strong><\/a>\u201d report, global liquid biopsy in cancer diagnostics market was valued at <strong>USD 6,953.15<\/strong> <strong>million<\/strong> in 2020, growing at a CAGR of <strong>16.64%<\/strong> during the forecast period from 2021 to 2026 to reach <strong>USD 16,500.05 million<\/strong> by 2026. Factors such as the rising incidence of various cancers, growing demand for minimally invasive procedures, increasing demand of precision medicine, technical innovation in product development among other factors are expected to drive the liquid biopsy in the cancer diagnostics market.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Alucent_Biomedical_Announces_Enrollment_of_First_Patient_in_First_in_Human_Natural_Vascular_Scaffolding_Clinical_Trial\"><\/span><strong>Alucent Biomedical Announces Enrollment of First Patient in First in Human Natural Vascular Scaffolding Clinical Trial<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On<strong> April 12, 2022<\/strong>, <strong>Alucent Biomedical Inc.<\/strong> announced the enrollment of the first patient in ACTIVATE II, an Australia-based First-in-Human clinical trial to evaluate the safety and efficacy of its revolutionary <strong>Natural Vascular Scaffolding (AlucentNVS)<\/strong> technology. The therapy is designed to open vessels and maintain patency without the use of permanent implants for the treatment of peripheral artery disease (PAD) of the lower extremities.&nbsp;<\/p>\n\n\n\n<p>The Alucent NVS Vessel Restoration System with Photoactivated Linking combines standard angioplasty with linking of the structural proteins in the wall of a blood vessel. The device is designed to restore the vessel\u2019s lumen and improve blood flow without introducing a foreign implant, such as a metallic stent. Alucent NVS photoactivated linking is also designed to mitigate the well-known adverse effects of angioplasty, such as vessel recoil. Treatment using this device is expected to provide sustained, improved blood flow thereby offering pain relief, limb preservation, and improved quality of life for patients.<\/p>\n\n\n\n<p>The first patient in the ACTIVATE II study was enrolled by Dr. Chris Delaney at Flinders Medical Centre in Adelaide. In total, the trial will enrol up to <strong>50 subjects<\/strong> with up to <strong>12 research sites<\/strong>. The primary endpoints of the study are freedom from composite investigational device, procedure-related Major Adverse Events, Primary Patency as assessed by Doppler Ultrasound, and freedom from clinically-driven target lesion revascularization (CD-TLR) at one year.<\/p>\n\n\n\n<p>ACTIVATE II follows the completion of enrollment for ACTIVATE I safety study of AlucentNVS within the United States. Pre-clinical testing of AlucentNVS in animal studies has shown acute and long-term safety and patency without the pro-inflammatory and mechanical risks of placing a rigid foreign implant into the blood vessel.&nbsp;<\/p>\n\n\n\n<p>Dr. Myles Greenberg, Alucent Biomedical\u2019s CEO, stated, <em>\u201cWe want to change that by offering a whole new way to treat these patients with AlucentNVS. Alucent\u2019s novel approach has the potential to change the way PAD is managed in the future.\u201d<\/em>According to <strong>DelveInsight\u2019s analysis<\/strong>, the increasing prevalence of lifestyle disorders such as high cholesterol, hypertension,\u00a0 growing prevalence of cardiovascular disorders, sedentary lifestyle habits are some factors collectively contributing to the increasing prevalence of peripheral artery disease. This in turn is motivating companies across the globe operating in this domain to bring forth innovative and advanced systems, thereby providing a positive growth outlook for the <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/peripheral-vascular-devices-market\" class=\"ek-link\">peripheral artery disease market<\/a><\/strong>.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Alcon Announces Launch of Dry Eye Treatment Device On April 04, 2022, Alcon Inc. announced the launch of their latest dry eye innovation, the Systane\u00ae iLux2\u00ae Meibomian Gland Dysfunction (MGD) Thermal Pulsation System. It is an all-in-one handheld device equipped with new imaging technology to capture infrared photos and HD video of the meibomian glands [&hellip;]<\/p>\n","protected":false},"author":6,"featured_media":17011,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":9,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[19155,18913,19153,2753,18799,420,19243,19244,19188],"industry":[17226],"therapeutic_areas":[17242,17228,17244],"class_list":["post-17002","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-cancer-diagnostics-market","tag-chronic-venous-insufficiency","tag-liquid-biopsy-in-cancer-diagnostics","tag-medical-device","tag-medtech-news","tag-news","tag-ophthalmic-devices-market","tag-peripheral-artery-disease-market","tag-peripheral-vascular-devices-market","industry-medical-devices","therapeutic_areas-cardiovascular-diseases","therapeutic_areas-oncology","therapeutic_areas-ophthalmology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>MedTech News and Updates | Alcon, I-VASC, Paige, Truvic, and Alucent<\/title>\n<meta name=\"description\" content=\"Alcon\u2019s Dry Eye Treatment Device; I-VASC Secures Series A Funding; Paige\u2019s AI Medical Device Software; TRUVIC\u2019s Prodigy Thrombectomy System\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-alcon-ivasc-paige-truvic-alucent\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"MedTech News and Updates | Alcon, I-VASC, Paige, Truvic, and Alucent\" \/>\n<meta property=\"og:description\" content=\"Alcon\u2019s Dry Eye Treatment Device; I-VASC Secures Series A Funding; Paige\u2019s AI Medical Device Software; TRUVIC\u2019s Prodigy Thrombectomy System\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-alcon-ivasc-paige-truvic-alucent\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2022-04-14T14:15:34+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-04-04T05:54:57+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/04\/14202307\/MedTech-News-for-Alcon-I-VASC-Paige-Truvic-and-Alucent.png\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"11 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"MedTech News and Updates | Alcon, I-VASC, Paige, Truvic, and Alucent","description":"Alcon\u2019s Dry Eye Treatment Device; I-VASC Secures Series A Funding; Paige\u2019s AI Medical Device Software; TRUVIC\u2019s Prodigy Thrombectomy System","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-alcon-ivasc-paige-truvic-alucent","og_locale":"en_US","og_type":"article","og_title":"MedTech News and Updates | Alcon, I-VASC, Paige, Truvic, and Alucent","og_description":"Alcon\u2019s Dry Eye Treatment Device; I-VASC Secures Series A Funding; Paige\u2019s AI Medical Device Software; TRUVIC\u2019s Prodigy Thrombectomy System","og_url":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-alcon-ivasc-paige-truvic-alucent","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2022-04-14T14:15:34+00:00","article_modified_time":"2023-04-04T05:54:57+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/04\/14202307\/MedTech-News-for-Alcon-I-VASC-Paige-Truvic-and-Alucent.png","type":"image\/png"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"11 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-alcon-ivasc-paige-truvic-alucent","url":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-alcon-ivasc-paige-truvic-alucent","name":"MedTech News and Updates | Alcon, I-VASC, Paige, Truvic, and Alucent","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-alcon-ivasc-paige-truvic-alucent#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-alcon-ivasc-paige-truvic-alucent#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/04\/14202307\/MedTech-News-for-Alcon-I-VASC-Paige-Truvic-and-Alucent.png","datePublished":"2022-04-14T14:15:34+00:00","dateModified":"2023-04-04T05:54:57+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/0d96a31a370c143ffdb481d985d7edfd"},"description":"Alcon\u2019s Dry Eye Treatment Device; I-VASC Secures Series A Funding; Paige\u2019s AI Medical Device Software; TRUVIC\u2019s Prodigy Thrombectomy System","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/medtech-news-for-alcon-ivasc-paige-truvic-alucent"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-alcon-ivasc-paige-truvic-alucent#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/04\/14202307\/MedTech-News-for-Alcon-I-VASC-Paige-Truvic-and-Alucent.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/04\/14202307\/MedTech-News-for-Alcon-I-VASC-Paige-Truvic-and-Alucent.png","width":772,"height":482,"caption":"MedTech News for Alcon, I-VASC, Paige, Truvic, and Alucent"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/0d96a31a370c143ffdb481d985d7edfd","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/f9314f22b8c5b61d496451e91f32488d2457ecb59283b7b2ad7e82d330b47aba?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/f9314f22b8c5b61d496451e91f32488d2457ecb59283b7b2ad7e82d330b47aba?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/arawat"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/04\/14202307\/MedTech-News-for-Alcon-I-VASC-Paige-Truvic-and-Alucent-300x187.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Cancer diagnostics market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Chronic Venous Insufficiency<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Liquid Biopsy in cancer diagnostics<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">medical device<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">MedTech News<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Ophthalmic Devices Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Peripheral Artery Disease Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Peripheral Vascular Devices Market<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Cancer diagnostics market<\/span>","<span class=\"advgb-post-tax-term\">Chronic Venous Insufficiency<\/span>","<span class=\"advgb-post-tax-term\">Liquid Biopsy in cancer diagnostics<\/span>","<span class=\"advgb-post-tax-term\">medical device<\/span>","<span class=\"advgb-post-tax-term\">MedTech News<\/span>","<span class=\"advgb-post-tax-term\">news<\/span>","<span class=\"advgb-post-tax-term\">Ophthalmic Devices Market<\/span>","<span class=\"advgb-post-tax-term\">Peripheral Artery Disease Market<\/span>","<span class=\"advgb-post-tax-term\">Peripheral Vascular Devices Market<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 4 years ago","modified":"Updated 3 years ago"},"absolute_dates":{"created":"Posted on Apr 14, 2022","modified":"Updated on Apr 4, 2023"},"absolute_dates_time":{"created":"Posted on Apr 14, 2022 7:45 pm","modified":"Updated on Apr 4, 2023 11:24 am"},"featured_img_caption":"MedTech News for Alcon, I-VASC, Paige, Truvic, and Alucent","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/17002","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=17002"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/17002\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/17011"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=17002"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=17002"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=17002"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=17002"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=17002"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}